Accendra Health earnings release, August 10, 2026

Accendra Health Inc (ACH) · Form 8-K, Item 2.02 · Filed · SEC filing

Accendra Health

Reports Second Quarter 2026 Financial Results

Reduced Total

Debt By $385 Million In Second Quarter

CEO Ed Pesicka

Announces Intention To Retire By The End of 2026

RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended

June 30, 2026. Unless otherwise noted, the results h erein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations.

“Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exit behind us. In the last six months, we have eliminated well over $125 million of annualized operating expense directly associated with this large commercial payor, and we are now beginning to reset our business for accelerated future growth. Additionally, we reduced outstanding debt by $385 million and comprehensively reset our debt maturity profile through our balance sheet optimization transaction which closed in June,” said Edward A. Pesicka, President & Chief Executive Officer, Accendra Health.

“We also saw continued progress on key growth initiatives and new strategic partnerships that have both topline and bottom line expansion opportunities that will begin to emerge in late 2026 and accelerate in 2027. These include the nationwide rollout of the Sleep Center of Excellence, new commercial agreements, and an increased emphasis on expense rationalization,” Pesicka concluded.

Earlier today, the Company announced in a separate press release that President & CEO Edward A. Pesicka has informed the Board of Directors that he intends to retire from his role by the end of 2026. Pesicka also plans to step down from the Board of Directors before the year's end. The Board of Directors maintains a comprehensive succession planning process which has previously identified potential candidates with the capabilities to succeed Pesicka and will leverage that preparation to select his successor in the coming months. During this period, Pesicka will continue to lead the business, drive the execution of the Company’s strategic priorities, and facilitate a smooth transition to the Company’s next

President and CEO once selected.¹

2026 Continuing Operations Financial Outlook

The company is updating its prior financial guidance for the full year

2026, summarized below.

Revenue: $2.45 billion - $2.55 billion

Adjusted EBITDA: $300 million - $320 million

Free cash flow: breakeven to slightly positive

Although the Company provides guidance for free cash flow and adjusted EBITDA (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, restructuring and acquisition charges which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s free cash flow or adjusted EBITDA guidance is provided. The outlook is based on certain assumptions, including, but not limited to market conditions, consumer demand, supply chain stability, interest rates, and other factors that are subject to the risk factors discussed in the Company’s filings with the SEC.

Investor Conference Call for Second Quarter 2026 Financial Results

Accendra Health will host a conference call for investors and analysts on Monday, August 10, 2026, at 8:00AM E.T. Participants may access the call via the toll-free dial-in number at

1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendrahealth.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.

Safe Harbor

Financial statements

Income Statement

Second Quarter Results(1) ($ in millions, except per share data)

Second Quarter Results(1) – 2Q26Second Quarter Results(1) – 2Q25Second Quarter Results(1) – YTD – 2026Second Quarter Results(1) – YTD – 2025
Net Revenue613.2681.91,2411,355.8
Loss from continuing operations, net of tax, GAAP-89.1-83.8-95.5-87.6
Adj. (loss) income from continuing operations, net of tax, Non-GAAP-14.320.5-17.443.7
Adj. EBITDA, Non-GAAP60.196.6118.5192.7
Free cash flow, Non-GAAP-25.115.2-27.150.7
Loss from continuing operations, net of tax, per common share, GAAP-1.16-1.09-1.25-1.14
Adj. (loss) income from continuing operations, net of tax, per common share, Non-GAAP-0.190.26-0.230.55

Income Statement

Three Months Ended June 30, — (dollars in thousands, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Net revenue613,234681,917
Operating costs and expenses:Cost of net revenue349,827357,315
Operating costs and expenses:Selling, general and administrative expenses243,560267,853
Operating costs and expenses:Transaction breakage fee80,000
Operating costs and expenses:Acquisition-related charges and intangible amortization29,22913,918
Operating costs and expenses:Exit and realignment charges, net25,7682,541
Operating costs and expenses:Total operating costs and expenses648,384721,627
Operating costs and expenses:Operating loss-35,150-39,710
Operating costs and expenses:Interest expense, net34,53926,009
Operating costs and expenses:Loss on modification and extinguishment of debt17,296
Operating costs and expenses:Transaction financing fees, net18,288
Operating costs and expenses:Other expense, net643942
Operating costs and expenses:Loss from continuing operations before income taxes-87,628-84,949
Operating costs and expenses:Income tax provision (benefit)1,442-1,127
Operating costs and expenses:Loss from continuing operations, net of tax-89,070-83,822
Operating costs and expenses:Loss from discontinued operations, net of tax-785,236
Operating costs and expenses:Net loss-89,070-869,058
Basic loss per common shareLoss from continuing operations, net of tax-1.16-1.09
Basic loss per common shareLoss from discontinued operations, net of tax-10.21
Basic loss per common shareNet loss-1.16-11.3
Diluted loss per common shareLoss from continuing operations, net of tax-1.16-1.09
Diluted loss per common shareLoss from discontinued operations, net of tax-10.21
Diluted loss per common shareNet loss-1.16-11.3

Income Statement

Six Months Ended June 30, — (dollars in thousands, except per share data)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue1,241,0141,355,801
Operating costs and expenses:Cost of net revenue699,579711,957
Operating costs and expenses:Selling, general and administrative expenses498,786530,223
Operating costs and expenses:Transaction breakage fee80,000
Operating costs and expenses:Acquisition-related charges and intangible amortization58,45837,374
Operating costs and expenses:Exit and realignment charges, net2,21616,166
Operating costs and expenses:Total operating costs and expenses1,259,0391,375,720
Operating costs and expenses:Operating loss-18,025-19,919
Operating costs and expenses:Interest expense, net66,88750,223
Operating costs and expenses:Loss on modification and extinguishment of debt17,296
Operating costs and expenses:Transaction financing fees, net18,288
Operating costs and expenses:Other expense, net1,6651,917
Operating costs and expenses:Loss from continuing operations before income taxes-103,873-90,347
Operating costs and expenses:Income tax benefit-8,336-2,715
Operating costs and expenses:Loss from continuing operations, net of tax-95,537-87,632
Operating costs and expenses:Loss from discontinued operations, net of tax-806,408
Operating costs and expenses:Net loss-95,537-894,040
Basic loss per common shareLoss from continuing operations, net of tax-1.25-1.14
Basic loss per common shareLoss from discontinued operations, net of tax-10.46
Basic loss per common shareNet loss-1.25-11.6
Diluted loss per common shareLoss from continuing operations, net of tax-1.25-1.14
Diluted loss per common shareLoss from discontinued operations, net of tax-10.46
Diluted loss per common shareNet loss-1.25-11.6

Balance Sheet

June 30, 2026 — (dollars in thousands)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents7,651281,989
Current assetsAccounts receivable, net120,08295,907
Current assetsInventories, net73,34574,435
Current assetsOther current assets70,37195,540
Current assetsTotal current assets271,449547,871
Current assetsPatient service equipment and other fixed assets, net of accumulated depreciation and amortization of $196,257 and $207,595208,666256,161
Current assetsOperating lease assets97,008109,099
Current assetsGoodwill1,228,1401,228,140
Current assetsIntangible assets, net78,007136,465
Current assetsOther assets, net224,142174,025
Current assetsTotal assets2,107,4122,451,761
Current liabilitiesAccounts payable352,798363,565
Current liabilitiesAccrued payroll and related liabilities41,83269,426
Current liabilitiesCurrent portion of long-term debt250,000
Current liabilitiesOther current liabilities271,586264,084
Current liabilitiesTotal current liabilities666,216947,075

Cash Flow

Three Months Ended June 30, — (dollars in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Operating activities:Net loss-89,070-869,058
Operating activities:Loss from discontinued operations, net of tax785,236
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Depreciation and amortization65,70042,986
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Share-based compensation expense4,0044,872
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Deferred income tax (benefit) provision-48,06013,184
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Changes in operating lease right-of-use assets and lease liabilities13-83
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Gain from sale and dispositions of patient service equipment-3,270-3,969
Changes in operating assets and liabilities:Accounts receivable, net-16,37917,146
Changes in operating assets and liabilities:Inventories-8,0604,673
Changes in operating assets and liabilities:Accounts payable-2,003-20,863
Changes in operating assets and liabilities:Net change in other assets and liabilities67,772-38,376
Changes in operating assets and liabilities:Other, net3,3474,657
Changes in operating assets and liabilities:Cash provided by operating activities from discontinued operations97,205
Changes in operating assets and liabilities:Cash (used for) provided by operating activities-26,00637,610
Investing activities:Additions to patient service equipment ($43,796 and $57,260) and other fixed assets-47,586-57,623
Investing activities:Proceeds from sale of patient service equipment15,30318,120
Investing activities:Additions to computer software-1,062-1,548
Investing activities:Other, net2,100-1,500
Investing activities:Cash used for investing activities from discontinued operations-10,366
Investing activities:Cash used for investing activities-31,245-52,917
Financing activities:Borrowings under Revolving Credit Agreement279,500853,200
Financing activities:Repayments under Revolving Credit Agreement-534,500-815,700
Financing activities:Proceeds from debt issuance1,237,315
Financing activities:Repayments of debt-1,237,315
Financing activities:Financing costs paid-16,791
Financing activities:Repurchase of common stock-5,153
Financing activities:Other, net-187-32
Financing activities:Cash used for financing activities from discontinued operations-616
Financing activities:Cash (used for) provided by financing activities-271,97831,699
Financing activities:Effect of exchange rate changes on cash and cash equivalents1,259
Financing activities:Net (decrease) increase in cash and cash equivalents-329,22917,651
Financing activities:Cash and cash equivalents at beginning of period (¹)336,88059,436
Financing activities:Cash and cash equivalents at end of period (¹)7,65177,087
Supplemental disclosure of cash flow information:Income taxes (refunded) paid, net-4385,333
Supplemental disclosure of cash flow information:Interest paid49,87838,358
Noncash investing activity:Unpaid purchases of patient service equipment and other fixed assets at end of period52,68473,437

Cash Flow

Six Months Ended June 30, — (dollars in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activities:Net loss-95,537-894,040
Operating activities:Loss from discontinued operations, net of tax806,408
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Depreciation and amortization127,44285,888
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Share-based compensation expense7,0949,293
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Deferred income tax (benefit) provision-45,4898,789
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Changes in operating lease right-of-use assets and lease liabilities135744
Adjustments to reconcile net loss to cash (used for) provided by operating activities:Gain from sale and dispositions of patient service equipment-58,779-9,322
Changes in operating assets and liabilities:Accounts receivable, net-24,17521,891
Changes in operating assets and liabilities:Inventories1,090-1,646
Changes in operating assets and liabilities:Accounts payable6,772-4,739
Changes in operating assets and liabilities:Net change in other assets and liabilities-1,403-56,441
Changes in operating assets and liabilities:Other, net6,7675,058
Changes in operating assets and liabilities:Cash provided by operating activities from discontinued operations30,661
Changes in operating assets and liabilities:Cash (used for) provided by operating activities-76,0832,544
Investing activities:Additions to patient service equipment ($85,139 and $101,744) and other fixed assets-89,232-103,416
Investing activities:Proceeds from sale of patient service equipment111,71835,004

Cash Flow

Three Months Ended June 30, — and total debt to non-GAAP measures used by management. (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Loss from continuing operations, net of tax, as reported (GAAP)-89,070-83,822
Income tax provision (benefit)1,442-1,127
Interest expense, net34,53926,009
Acquisition-related charges and intangible amortization (1)29,22913,918
Transaction breakage fee (2)80,000
Exit and realignment charges, net (3)25,7682,541
Transaction financing fees, net (4)18,288
Litigation and related charges (5)121
Other depreciation and amortization (6)36,47235,422
Stock compensation (7)4,0044,861
Loss on modification and extinguishment of debt (8)17,296
Other (9)409424
Adjusted EBITDA (non-GAAP)60,08996,635
Non-cash convert to sale write off expense (10)8,48214,152
Patient service equipment capital expenditures-43,796-57,260
Interest paid-49,878-38,358
Free cash flow (non-GAAP)-25,10315,169

Cash Flow

Six Months Ended June 30, — and total debt to non-GAAP measures used by management. (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Loss from continuing operations, net of tax, as reported (GAAP)-95,537-87,632
Income tax benefit-8,336-2,715
Interest expense, net66,88750,223
Acquisition-related charges and intangible amortization (1)58,45837,374
Transaction breakage fee (2)80,000
Exit and realignment charges, net (3)2,21616,166
Transaction financing fees, net (4)18,288
Litigation and related charges (5)64391
Other depreciation and amortization (6)68,98470,758
Stock compensation (7)7,6078,952
Loss on modification and extinguishment of debt (8)17,296
Other (9)817848
Adjusted EBITDA (non-GAAP)118,456192,653
Non-cash convert to sale write off expense (10)18,89825,683
Patient service equipment capital expenditures-85,139-101,744
Interest paid-79,324-65,845
Free cash flow (non-GAAP)-27,10950,747
Full release

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, uncertainty about the time required to select and appoint the Company’s next President and CEO, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on

Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A.

Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished... (truncated)al results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

About Accendra Health

Accendra

Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology and ostomy, visit www.accendrahealth.com.²

Accendra Health, Inc.

Condensed Consolidated Statements of Operations (unaudited)

(dollars in thousands, except per share data)³

Accendra Health, Inc.

Condensed Consolidated Statements of Operations (unaudited)

(dollars in thousands, except per share data)⁴

Accendra Health, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(dollars in thousands)⁵

Accendra Health, Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(dollars in thousands)⁶

Accendra Health, Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(dollars in thousands)⁷

Accendra Health, Inc.

Net Loss Per Common Share (unaudited)

(dollars in thousands, except per share data)

Share-based awards of approximately 1.1 million for the three months ended June 30, 2026 and 2.5 million for the three months ended June 30, 2025 were excluded from the calculation of diluted loss per common share as the effect would be anti-dilutive.⁸

Accendra Health, Inc.

Net Loss Per Common Share (unaudited)

(dollars in thousands, except per share data)

Share-based awards of approximately 1.2 million for the six months ended June 30, 2026 and 2.2 million for the six months ended June 30, 2025 were excluded from the calculation of diluted loss per common share as the effect would be anti-dilutive.⁹

Accendra Health, Inc.

GAAP/Non-GAAP Reconciliations (unaudited)

(dollars in thousands, except per share data)

The following table provides a reconciliation of reported loss from continuing operations, net of tax and loss from continuing operations, net of tax, per common share to non-GAAP measures used by management.¹⁰

Accendra Health, Inc.

GAAP/Non-GAAP Reconciliations (unaudited), continued

The following tables provide reconciliations of loss from continuing operations, net of tax and total debt to non-GAAP measures used by management.¹¹

Accendra Health, Inc.

GAAP/Non-GAAP Reconciliations (unaudited), continued

The following items have been excluded from our non-GAAP financial measures:

(1)

Acquisition-related charges and intangible amortization for the three and six months ended June 30, 2025 includes $6.4 million and $22 million of acquisition-related charges related to the terminated acquisition of Rotech, which consisted primarily of legal and professional fees. Acquisition-related charges and intangible amortization also includes amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to acquisitions, including transaction costs necessary to consummate acquisitions, which consist of investment banking advisory fees and legal fees, director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, information technology (IT) integration costs and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results.

(2)

Transaction breakage fee represents a cash payment to Rotech of $80 million during the three and six months ended June 30, 2025 for the termination of the Rotech acquisition.

(3)

During the three and six months ended June 30, 2026 exit and realignment charges, net were $26 million and $2.2 million and primarily included a $0.6 million loss and $(51) million gain on sales of patient service equipment in connection with the contract termination with a commercial Payor, P&HS Sale related costs, including reimbursable separation costs of $22 million and

$48 million, $2.1 million and $2.5 million in professional fees and charges related to IT and other strategic initiatives of $1.0 million and $3.0 million. Exit and realignment charges, net were $2.5 million and $16 million for the three and six months ended June 30, 2025 and primarily included professional fees associated with strategic initiatives of $1.9 million and $8.1 million.

During the six months ended June 30, 2025 exit and realignment charges, net also included $6.8 million related to wind-down costs of Fusion 5.

These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis.

(4)

Transaction financing fees, net for the three and six months ended June 30, 2025 includes $12 million in net interest paid and $6.7 million in recognition of previously deferred debt issuance costs, all in connection... (tr previously expected Rotech acquisition.

(5)

Litigation and related charges includes settlement costs and related charges of legal matters. These costs do not occur in the ordinary course of our business and are inherently unpredictable in timing and amount.

(6)

Other depreciation and amortization relates to patient service equipment and other fixed assets, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization.

(7)

Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization.

(8)

Loss on modification and extinguishment of debt of $17 million includes $16 million of debt modification third party fees and $0.8 million in recognition of previously deferred debt issuance costs from the completion of the Balance Sheet Optimization Transaction.

(9)

For the three and six months ended June 30, 2026 and 2025, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the U.S.

(10)

Non-cash convert to sale write off expense includes non-cash charges primarily for equipment converted from rental to sales, excluding such amounts captured within exit and realignment charges, net. This reflects the non-cash write-off of the remaining book value of patient service equipment at the time of sale. The purchase of patient service equipment is captured within capital expenditures and is subsequently charged to our statements of operations through normal depreciation and this non-cash convert to sale write off expense. This line item does not include non-cash write off expense associated with sales of patient service equipment in connection with the contract termination with a commercial Payor, as such amounts are captured within exit and realignment charges, net.¹²

(11)

These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.

Use of Non-GAAP Measures

This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect the Company’s core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company’s performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.

Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company’s performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.

CONTACT:

Investors

Will Parrish

Vice President, Strategy, Corporate Development, & Investor Relations

Investor.Relations@accendra.com

Media

Darla Turner media@accendra.com

ACH-CORP

ACH-IR

SOURCE:

Accendra Health, Inc.¹³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Accendra Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.